Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Last trade$20.98
Day change-$0.25 (-1.18%)
Day range$20.76 – $21.22
Volume770,274
Market cap$7.40B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$7.4B
Price / earnings
55.49×
Price / book
13.92×
Price / sales
2.31×
EV / sales
3.26×
EV / EBITDA
14.44×
Profitability
Earnings per share
$0.38
Return on assets
2.53%
Return on equity
25.09%
Dividend yield
0%
Liquidity and leverage
Debt / equity
6×
Current ratio
1.87×
Quick ratio
1.24×
Cash ratio
0.14×
Cash flow
Price / cash flow
40.95×
Price / free cash flow
83.87×
Free cash flow
$88.2M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for AMRX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$862.68M
$796.2M
$722.52M
$814.32M
$784.51M
$724.51M
$695.42M
$730.52M
Cost of revenue
$528.57M
$461.69M
$402.41M
$517.13M
$510.54M
$438.26M
$439.53M
$467.65M
Gross profit
$334.12M
$334.51M
$320.11M
$297.19M
$273.97M
$286.25M
$255.89M
$262.87M
Selling, general and administrative
$139.65M
$148.72M
$138.86M
$146.46M
$137.82M
$124.27M
$118.29M
$128.69M
Research and development
$68.37M
$39.02M
$38.38M
$34.82M
$63.35M
$47.96M
$40.04M
$54.27M
Total operating expenses
$238.7M
$204.74M
$178.34M
$190.4M
$203.63M
$174.88M
$155.54M
$188.01M
Operating income
$95.42M
$129.77M
$141.77M
$106.79M
$70.34M
$111.37M
$100.35M
$74.86M
Interest expense
-$58.91M
-$55.04M
-$53.36M
$184.85M
-$62.81M
-$65.1M
-$56.94M
$196.93M
Income before taxes
$15.06M
$70.99M
$80.18M
$55.24M
-$5.22M
$51.71M
$37.49M
-$15.32M
Income taxes
$2.75M
$1.38M
$2.18M
$5.66M
-$23.36M
$16.1M
$12.87M
$5.42M
Net income
$12.31M
$69.61M
$78M
$49.57M
$18.13M
$35.61M
$24.62M
-$20.74M
Net income attributable to common shareholders
-$21.7M
$57.66M
$62.26M
$35.08M
$2.37M
$22.42M
$12.2M
-$31.08M
EBITDA
$178.43M
$193.78M
$191.46M
$158.49M
$124.56M
$172.12M
$161.08M
$143.27M
Basic earnings per share
-$0.06
$0.18
$0.20
$0.11
$0.01
$0.07
$0.04
-$0.10
Diluted earnings per share
-$0.06
$0.18
$0.19
$0.11
$0.01
$0.07
$0.04
-$0.10
Recent news
Company coverage with links to the original publishers.
Summit Therapeutics received an FDA Complete Response Letter (CRL) for ivonescimab plus chemotherapy in NSCLC patients, declining approval due to insufficient evidence of effectiveness. While the HARMONi trial met its progression-free survival endpoint, it failed to demonstrate statistically significant overall survival benefit. The decision represents a major regulatory setback, delaying the company's first marketed product and U.S. commercial revenues.
uniQure's lead gene therapy candidate, ifezuntirgene inilparvovec, for Huntington's disease has received FDA Priority Review with a May 1, 2027 decision date. The company plans to launch a confirmatory study by end of 2026 targeting 200 patients. While the regulatory milestone drove a 17.5% stock surge, mixed clinical data, widening loss estimates, and pipeline risks temper the outlook. The company maintains a strong cash position of $768.4 million expected to fund operations through 2030.
Kodiak Sciences reported a Q3 2026 loss of $1.05 per share, wider than expected, as R&D expenses rose 15.5% year-over-year. However, the company announced positive phase III DAYBREAK study results for lead candidate Zenkuda and KSI-501, both meeting primary endpoints against Regeneron's Eylea. Kodiak plans to submit a BLA for Zenkuda by year-end and expects KSI-101 data in December 2026.
Altimmune reported a Q3 2026 loss of 15 cents per share, missing consensus estimates by one cent. R&D expenses surged 80.6% to $27 million due to ongoing pemvidutide clinical studies. The company has $480 million in cash expected to fund operations into 2029. Stock declined 17% following the announcement due to concerns over rising development costs and funding uncertainty for the planned phase III AUD program.
Aura Biosciences completed enrollment and dosing in its phase III CoMpass study evaluating bel-sar for early choroidal melanoma treatment. Top-line data is expected in the second half of 2027. If successful, bel-sar could become the first FDA-approved frontline vision-preserving therapy for this indication. The company is also exploring bel-sar for choroidal metastases and ocular surface cancers, with updates expected in Q1 2027. AURA shares have risen 39.6% year-to-date.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.